focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,756.00
Bid: 1,753.00
Ask: 1,754.00
Change: -19.00 (-1.07%)
Spread: 1.00 (0.057%)
Open: 1,770.00
High: 1,770.00
Low: 1,740.00
Prev. Close: 1,775.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Blue Chips Underperform On Big Earnings Day

Wed, 27th Apr 2016 11:13

LONDON (Alliance News) - Shares in the UK were mixed Wednesday midday, with large-cap stocks under-performing mid- and small-caps and with a US Federal Reserve interest rate decision due after the London market close.

Shares in blue-chip bank Barclays were slightly lower after its first-quarter earnings issued prior to the market open, while those of drug-making giant GlaxoSmithKline were flat after reporting at midday an "encouraging" start to 2016.

The FTSE 100 index was down 0.4%, or 21.91 points, at 6,262.61 at midday. At the same time, the FTSE 250 was up 0.4% at 17,016.66 and the AIM All-Share was flat at 729.44.

In Paris, the CAC 40 index was up 0.2%, and the DAX 30 in Frankfurt was adding 0.4%.

"Risk aversion is once more creeping into European markets as last week's gains are eroded away ahead of tonight's Federal Open Market Committee announcement," said IG analyst Joshua Mahony, noting that "it comes as no surprise that some element of profit taking should take hold with such a significant risk event ahead of us."

The Fed monetary policy decision is scheduled for 1900 BST. Economists overwhelmingly expect the central bank to leave its Federal Funds rate target unchanged, but a calmer global macroeconomic backdrop could mean the Fed hints at a rate rise at its next meeting in June.

IG's Mahony said that, with markets implying the chances of a rate hike stand at 0% probability and a rate cut at 2%, the interesting part of the meeting will be the tone of the Fed's statement with regards to future rate hikes. Mahony added that, with a 21% probability of a June rate hike, the Fed "will want to align expectations with the likeliness of it happening".

Following technology giant's Apple report of a drop in profit in the second-quarter, hurt largely by a double-digit revenue decline that reflected weak iPhone sales, the US corporate calendar brings on Wednesday first-quarter results from Facebook after the Wall Street close.

Wall Street futures were down, with the Dow 30 pointed down 0.2% and the S&P down 0.3%. The Nasdaq 100 was likely to suffer most from the results reported by Nasdaq-listed Apple Tuesday after the US equities close, called down 1.1%.

In the economic calendar, US goods trade balance is due at 1330 BST, pending home sales at 1500 BST, and the Energy Information Administration's crude oil stocks change at 1430 BST.

In addition to the Fed this week is a Bank of Japan policy decision set for early Thursday. The Japanese central bank will conclude its two-day policy meeting, with analysts widely expecting it to announce a slew of measures to help weaken the yen.

The UK economy grew at a slower pace, as expected, in the first quarter, preliminary estimates from the Office for National Statistics showed. Gross domestic product grew 0.4%, from a quarter ago, when it expanded 0.6%. This was in line with expectations.

Output increased in the dominant services sector by 0.6%. The other three main industrial groupings within the economy decreased, with production falling by 0.4%, construction output by 0.9% and agriculture by 0.1%.

On a yearly basis, UK GDP grew 2.1% in the first quarter, slightly faster than the expected growth of 2.0%.

"This is not a cause for concern," said Berenberg analyst Kallum Pickering, noting that it was anticipated. "The slowdown was caused by largely idiosyncratic and transitory risks, namely the financial market rout at the start of the year and the forthcoming EU referendum on June 23."

Another report from the ONS showed the UK index of services rose 2.5% in February from last year, with the largest contribution coming from distribution, hotels and restaurants and business services and finance. Month-on-month, services output edged up 0.1%, the same pace of growth as in January.

The pound gyrated heavily before and after the economic data, with sterling reaching an intraday high of USD1.4621 prior and then declining to a low of USD1.4550 shortly afterwards. The pound stabilized by midday, quoted at USD1.4600.

On the London Stock Exchange, Worldpay Group was up 2.6%, benefiting from an upgrade by UBS to Buy from Neutral. The Swiss bank said Worldpay's exposure to online transactions and significant investment in new value-added services will enable the company to outgrow its peers.

Shares in events and business publishing company Informa were up 1.2%, supported by an upgrade by Barclays to Overweight from Equal Weight.

Barclays itself was having an intense day following its first-quarter earnings. The bank said the results showed a core business in rude health even as the bank saw a 25% drop in pretax profit.

Pretax profit fell to GBP793 million in the three months ended March 31, Barclays said, down from GBP1.06 billion the corresponding quarter a year earlier, with income net of insurance claims down 11% to GBP5.04 billion and credit impairment charges up 15% to GBP443 million. The results were ahead of analyst expectations, reflecting a strong performance in the bank's core business and resilience in its investment banking business.

"In our view, the results reflect relative resilience, with notable outperformance versus peers in investment banking where revenues fell just 6% Q1/Q1," said Investec. Meanwhile, Jefferies said: "Barclays' first-quarter is uncontroversial in our view. The overall message is that the new CEO is executing well on plans, and we do not see consensus estimates moving either way."

Shares in Barclays opened higher Wednesday, reaching 182.00 pence, their highest level since early-February. However, the stock has declined since, trading down 0.5% at 173.10p at midday.

Emerging-market-focused peer Standard Chartered was down 3.5%, among the worst blue-chip performers, having been downgraded to Sell from Hold by Deutsche Bank. The stock was giving back only part of its gains on Tuesday, when it added 9.8%, reaching its highest level in 2016, after its first-quarter loan impairment charges and capital strength proved better than the market had expected.

Amec Foster Wheeler was up 3.2%, among the best performers in the FTSE 250. The company said it has appointed Jonathan Lewis, who has held several senior roles at US giant Halliburton, as its new chief executive as the company reported a drop in revenue in the first quarter of 2016.

The FTSE 250-listed oilfield services company said Lewis will takeover as chief executive from the start of June. Current interim Chief Executive Ian McHoul will step down from his role but remain as Amec Foster Wheeler's chief financial officer.

McCarthy & Stone was down 5.4% after funds managed by Anchorage Capital, TPG Special Situations Partners, Goldman Sachs European Special Situations Group and Strategic Value Partners sold 85.0 million shares in the retirement housebuilder, increased from the 75.0 million they had initially planned to sell.

The gross proceeds from the sale to the selling investors were around GBP200.0 million. Following the sale, Anchorage holds a 7.6% stake, TPG a 3.9% stake, Goldman Sachs a 3.9% stake and Strategic Value Partners a 4.2% stake.

Transport company Stagecoach Group was down 3.5% after saying like-for-like revenue grew in the first 48 weeks of its financial year in most of its operations, with only its North American arm suffering a decline. However, Liberum said that although revenue growth trends at the other divisions appear similar to the last update, "we see downside risk to 2017 estimates. Combined with bus re-regulation risk and looming rail franchise renewals, caution is still warranted."

Specialty chemicals company Elementis was down 1.5%. The group said it was working to manage its margins to keep its performance in line for 2016 following a mixed start to the year. The company said sales for its coatings and personal care segments in its Specialty Products division were "satisfactory" in the first quarter to the end of March, but total sales were down 7.0% amid a slump in oilfield revenue.

By Daniel Ruiz; danielruiz@alliancenews.com

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more
20 Feb 2024 15:10

PRESS: AJ Bell founder to join Applied Nutrition ahead of IPO - Sky

(Alliance News) - Supplements maker Applied Nutrition, plotting a London stock market float, is to add AJ Bell PLC founder Andy Bell as its chair, Sky News reported on Tuesday.

Read more
20 Feb 2024 08:55

IN BRIEF: Diageo welcomes GSK's CFO as non-executive director

Diageo PLC - London-based brewer and distiller sells more than 200 drinks brands, including Guinness stout, Captain Morgan rum and Johnnie Walker whisky - Appoints GSK PLC's chief financial officer and executive director, Julie Brown, as a non-executive director. Says she will succeed Alan Stewart as chair of the audit committee after his retirement following the firm's annual general meeting in September. Chair Javier Ferran says: "Julie brings many years of experience in financial, commercial and strategic roles in international companies operating in highly regulated industries. She is strongly committed to enabling diversity in business and to creating sustainable, long-term value for stakeholders. I look forward to her contribution to Board discussions and to working with her in progressing Diageo's ambition to be one of the most trusted and respected consumer products companies in the world."

Read more
15 Feb 2024 14:44

UK dividends calendar - next 7 days

Friday 16 February 
JPMorgan Asia Growth & Income PLCdividend payment date
JPMorgan Japan Small Cap Growth & Income PLCdividend payment date
Murray International Trust PLCdividend payment date
Premier Miton Group PLCdividend payment date
Schroder Oriental Income Funddividend payment date
Solid State PLCdividend payment date
Monday 19 February 
no events scheduled 
Tuesday 20 February 
Invesco Bond Income Plus Ltd 
Wednesday 21 February 
no events scheduled 
Thursday 22 February 
abrdn Asia Focus PLCex-dividend payment date
Alumasc Group PLCex-dividend payment date
AstraZeneca PLCex-dividend payment date
BlackRock Throgmorton Trust PLCex-dividend payment date
Braemar PLCex-dividend payment date
easyJet PLCex-dividend payment date
Ecofin US Renewables Infrastructure Trust PLCex-dividend payment date
Endeavour Mining PLCex-dividend payment date
FRP Advisory Group PLCex-dividend payment date
Gateley Holdings PLCex-dividend payment date
GSK PLCex-dividend payment date
Hercules Site Services PLCex-dividend payment date
Jersey Electricity PLCex-dividend payment date
Land Securities Group PLCex-dividend payment date
Molten Ventures VCT PLCex-dividend payment date
Northern Bear PLCex-dividend payment date
Redrow PLCex-dividend payment date
Samuel Heath & Sons PLCex-dividend payment date
Titon Holdings PLCex-dividend payment date
Unilever PLCex-dividend payment date
Van Elle Holdings PLCex-dividend payment date
Virgin Money UK PLCex-dividend payment date
Witan Investment Trust PLCex-dividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
15 Feb 2024 11:02

Berenberg hikes target price on GSK

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker GSK from £16.50 to £18.20 on Thursday, stating the group was moving closer to offsetting losses associated with the expiry of its patent on HIV drug dolutegravir.

Read more
15 Feb 2024 09:45

LONDON BROKER RATINGS: Jefferies cuts Kingfisher but Citi raises

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
15 Feb 2024 08:49

GSK completes USD1.4 billion purchase of respiratory firm Aiolos Bio

(Alliance News) - GSK PLC on Thursday said it has completed the acquisition of Aiolos Bio Ltd, expanding its respiratory portfolio with a potential "best-in-class" asthma treatment.

Read more
13 Feb 2024 16:53

LONDON MARKET CLOSE: Stocks in red amid sticky US inflation data

(Alliance News) - Stock prices in London closed in the red on Tuesday, after a key US inflation reading came in hotter-than-expected.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.